Oteseconazole
Vivjoa (oteseconazole) is a small molecule pharmaceutical. Oteseconazole was first approved as Vivjoa on 2022-04-26. It is used to treat vulvovaginal candidiasis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Vivjoa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oteseconazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIVJOA | Mycovia Pharmaceuticals | N-215888 RX | 2022-04-26 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vivjoa | New Drug Application | 2022-07-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| vulvovaginal candidiasis | EFO_0007543 | D002181 | B37.3 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OTESECONAZOLE, VIVJOA, MYCOVIA PHARMS | |||
| 2032-04-26 | GAIN | ||
| 2027-04-26 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vulvovaginal candidiasis | D002181 | EFO_0007543 | B37.3 | — | 2 | 3 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Onychomycosis | D014009 | B35.1 | — | 1 | — | — | — | 1 | |
| Tinea pedis | D014008 | EFO_0007512 | B35.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OTESECONAZOLE |
| INN | oteseconazole |
| Description | Oteseconazole is an organic molecular entity. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 1340593-59-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3311228 |
| ChEBI ID | — |
| PubChem CID | 77050711 |
| DrugBank | DB13055 |
| UNII ID | VHH774W97N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 76 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more
